Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Operating Leases (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Operating Leases for 3 consecutive years, with $52.7 million as the latest value for Q2 2024.

  • On a quarterly basis, Operating Leases rose 29.09% to $52.7 million in Q2 2024 year-over-year; TTM through Jun 2024 was $52.7 million, a 29.09% increase, with the full-year FY2023 number at $46.7 million, up 20.57% from a year prior.
  • Operating Leases was $52.7 million for Q2 2024 at Century Therapeutics, up from $44.3 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $52.7 million in Q2 2024 to a low of $14.4 million in Q1 2022.
  • A 3-year average of $39.1 million and a median of $41.0 million in 2023 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: soared 185.29% in 2023, then grew 7.49% in 2024.
  • Century Therapeutics' Operating Leases stood at $38.7 million in 2022, then increased by 20.57% to $46.7 million in 2023, then rose by 12.98% to $52.7 million in 2024.
  • Per Business Quant, the three most recent readings for IPSC's Operating Leases are $52.7 million (Q2 2024), $44.3 million (Q1 2024), and $46.7 million (Q4 2023).